Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Safety and Efficacy of Universal CAR-T Cells Targeting BCMA in the Treatment of Refractory AQP4 Antibody Positive Neuromyelitis Optica Spectrum Disease

NCT06633042 is registered in ClinicalTrials.gov with Bioray Laboratories as lead sponsor.

NCT NCT06633042
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06633042 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Safety and Efficacy of Universal CAR-T Cells Targeting BCMA in the Treatment of Refractory AQP4 Antibody Positive Neuromyelitis Optica Spectrum Disease
Lead sponsor
Bioray Laboratories
Phase
Phase 1
Overall status
Not yet recruiting
Start date
November 25, 2024
Completion date
December 12, 2025
Enrollment
18 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

autoimmune disease